Sign inCreate account

Report workspace tools

NCT07338370RECRUITINGanonymous

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Sponsor

Source record

Ain Shams University

Phase

Source record

Not classified

Modality

AI-normalized

small molecule

Target

AI-normalized

Ibuprofen (Brufen®)

Indication / condition

AI-normalized

Neonatal Prematurity

Intervention

Source record

Ibuprofen (Brufen®)

Source & freshness

Source record

NCT ID

NCT07338370

Original source

ClinicalTrials.gov

Source last updated

Jan 13, 2026

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07338370

Title

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Sponsor

Ain Shams University

Status

RECRUITING

Phase

Detailed source ingestion pending

Condition raw

Neonatal Prematurity, Patent Ductus Arteriosus in Preterm Infants, Prostaglandins

Condition normalized

Neonatal Prematurity, Patent Ductus Arteriosus in Preterm Infants, Prostaglandins

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Ibuprofen (Brufen®)

Target normalized

Ibuprofen (Brufen®)

Interventions

Ibuprofen (Brufen®)

Public preview

Source record

prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07338370

Status

RECRUITING

Phase

N/A

Sponsor

Ain Shams University

Executive brief

Investment-Ready Snapshot

prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 13, 2026
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07338370

Indication

Neonatal Prematurity

Modality

small molecule

Target

Ibuprofen (Brufen®)

Intervention

Ibuprofen (Brufen®)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.